# TABLE E1.

# Subject demographics

	Peripheral blood		Lymph node
	Allergic	Non-allergic	Asthmatic
Subjects	10	7	2
Men/women	3/7	2/5	1/1
Age (y)	36 ± 10	35 ± 13	19 ± 1
Race or ethnicity			
White	8	6	1
African American	0	0	0
Hispanic	0	0	1
Asian or Pacific Islander	2	1	0
Total IgE <sup>a</sup>	174 ± 53	33 ± 17	N/A
Specific IgE (number of positive subjects) <sup>b</sup>			
Dermatophagoides farinae	6	0	N/A
Dermatophagoides pteronyssinus	6	0	N/A
Bermuda grass	5	0	N/A
Cat dander	4	0	N/A
Active allergic rhinitis symptoms			
(at time of study blood draw)	10	0	N/A
Positive skin/ImmunoCap testing	10	0	N/A
On allergy medications (AH, ICS) <sup>c,d</sup>	0	0	N/A

 $^{a}P < 0.05.$ 

<sup>b</sup>Allergic subjects were sensitized to at least one aero-allergen

<sup>c</sup>Allergy medication use in one month prior to blood draw. AH = antihistamine, ICS = intranasal corticosteroid

<sup>d</sup>None of the subjects were former or current smokers, on oral corticosteroids or other chronic oral medications, or diagnosed with any chronic medical diseases other than allergic rhinitis (if in allergic group).



# Lymph Node T<sub>FH</sub> Gating Strategy







# **Supplementary Figure Legends:**

## TABLE E1. Subject demographics.

# FIG E1. FACS Gating strategy to detect $B_{REGS}$ and $CD25^{hi} B_{REGS}$ in human lung lymph nodes.

**A**, Human lung lymph node  $B_{REGS}$  were identified from the lung lymph node lymphocyte population as CD19<sup>+</sup>CD73<sup>-</sup>CD25<sup>+</sup>CD71<sup>+</sup> using the gating strategy shown. **B**, Human lung lymph nodes  $B_{REGS}$  from an asthmatic individual were analyzed using isotype controls to analyze their total CD25<sup>+</sup> and CD25<sup>hi</sup> subsets.

# FIG E2. FACS Gating strategy to detect $T_{FH}$ -like cells in human lung lymph nodes.

 $T_{FH}$ -like cells from an asthmatic human lung lymph node were identified from the lung lymph node lymphocyte population as CD4<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup> using the gating strategy shown.

# FIG E3. Cytokine production by $B_{\text{REGS}}$ and $T_{\text{FH}}$ cells.

**A**, IL-10 protein levels measured by ELISA in supernatants of sorted  $B_{REGS}$  from a non-allergic subject. **B**, IL-21 mRNA expression quantitated by qPCR in sorted  $T_{FH}$  cells from a non-allergic subject.

#### **Supplementary Methods:**

### Cell Sorting

Human peripheral whole blood was layered over a ficoll density gradient to isolate PBMCs.  $B_{REGS}$  and  $T_{FH}$ -like cells were sorted by fluorescently labeling PBMCs to identify  $B_{REGS}$  using CD19, CD73, CD25, and CD71 and  $T_{FH}$ -like cells using CD4, CXCR5, and PD-1 (eBioscience, San Diego, CA). Labeled PBMCs were sorted into  $B_{REGS}$  and  $T_{FH}$ -like cells using a FACSAria II cell sorter (BD Biosciences, Franklin Lakes, NJ).

#### Cell cultures

Sorted B<sub>REGS</sub> and T<sub>FH</sub> cells (>99% pure) were cultured in an RPMI-based media, supplemented with 10% FBS, 100 U/ml penicillin/streptomycin, 2mM L-glutamine, 0.1% 2-mercaptoethanol, and 20 ng/ml IL-2 (R&D Systems, Inc., Minneapolis, MN). Cells were plated at  $5x10^5$  cells/well in a 96-well plate. B<sub>REGS</sub> were stimulated with 10 µg/ml CpG ODN 2006 (InvivoGen USA, San Diego, CA) and T<sub>FH</sub> cells were stimulated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 antibodies (eBioscience) for 72 hours in humidified 5% CO<sub>2</sub> at 37°C. Supernatants from stimulated (and unstimulated controls) were collected for cytokine quantification and cells were lysed for RNA extraction.

#### IL-10 ELISA

IL-10 was measured using a human IL-10 ELISA kit (GenWay Biotech, Inc., San Diego, CA) from stimulated and unstimulated  $B_{REG}$  cell culture supernatants. IL-10 assay sensitivity is < 0.05 pg/ml.

#### Flow cytometry

Samples were analyzed using either a FACSAria II cell sorter or a Novocyte Flow Cytometer (ACEA Biosciences, Inc., San Diego, CA) and analyzed using FlowJo software (version 10.0.7, Tree Star, Inc., Ashland, OR). The antibodies used in this study include: CD4-APC/Cy7, PD-1-BV 421, CD25 BV605 (BioLegend, San Diego, CA), CXCR5-PE, CD19 PerCP/Cy5.5, CD73 APC, CD71 FitC (eBioscience).

#### IL-21 quantitative PCR

RNA was isolated from cultured  $T_{FH}$  cells using the PicoPure RNA Isolation Kit (Arcturus Therapeutics, San Diego, CA). Synthesis of cDNA was performed using a cDNA kit (Clontech Laboratories, Inc., Mountain View, CA) and qPCR was performed using the Mx3000 qPCR system (Agilent Technologies, Inc., Santa Clara, CA), TaqMan Universal PCR Master Mix (Life Technologies Corporation, Carlsbad, CA), and IL-21 primers (Life Technologies, Carlsbad, CA). The housekeeping gene GAPDH (Life Technologies) was used to normalize quantifications. Relative mRNA expression of IL-21 was calculated by using the  $\Delta\Delta$  comparative cycle threshold method.

#### **Supplementary References**

E1. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5+CD4+T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013;39:770-81.

E2. Tsai LM, Yu D. Follicular helper T-cell memory: establishing new frontiers during antibody response. Immunol Cell Biol 2014;92:57-63.

E3. Cooper PR, Kurten RC, Zhang J, Nicholls DJ, Dainty IA, Panettieri RA. Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms. Br J Pharmacol. 2011;163:521-32.

E4. Yang X, Yang J, Chu Y, Xue Y, Xuan D, Zheng S, et al. T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus. PLoS One 2014;9:e88441.

E5. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117:530-41.